- Home
- INCY vs ZBRA Comparison
INCY vs ZBRA Comparison
Compare INCY & ZBRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ZBRA
- Stock Information
- Founded
- INCY 1991
- ZBRA 1969
- Country
- INCY United States
- ZBRA United States
- Employees
- INCY N/A
- ZBRA N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ZBRA Industrial Machinery/Components
- Sector
- INCY Health Care
- ZBRA Industrials
- Exchange
- INCY Nasdaq
- ZBRA Nasdaq
- Market Cap
- INCY 16.1B
- ZBRA 16.2B
- IPO Year
- INCY 1993
- ZBRA 1991
- Fundamental
- Price
- INCY $86.85
- ZBRA $305.01
- Analyst Decision
- INCY Buy
- ZBRA Buy
- Analyst Count
- INCY 20
- ZBRA 8
- Target Price
- INCY $80.67
- ZBRA $351.13
- AVG Volume (30 Days)
- INCY 1.7M
- ZBRA 474.0K
- Earning Date
- INCY 10-28-2025
- ZBRA 10-28-2025
- Dividend Yield
- INCY N/A
- ZBRA N/A
- EPS Growth
- INCY 900.04
- ZBRA 138.37
- EPS
- INCY 4.37
- ZBRA 10.59
- Revenue
- INCY $4,584,996,000.00
- ZBRA $5,190,000,000.00
- Revenue This Year
- INCY $16.36
- ZBRA $8.47
- Revenue Next Year
- INCY $10.82
- ZBRA $7.33
- P/E Ratio
- INCY $19.80
- ZBRA $28.92
- Revenue Growth
- INCY 18.87
- ZBRA 19.12
- 52 Week Low
- INCY $53.56
- ZBRA $205.73
- 52 Week High
- INCY $88.66
- ZBRA $427.76
- Technical
- Relative Strength Index (RSI)
- INCY 59.41
- ZBRA 46.74
- Support Level
- INCY $81.09
- ZBRA $290.56
- Resistance Level
- INCY $88.66
- ZBRA $303.78
- Average True Range (ATR)
- INCY 1.90
- ZBRA 7.13
- MACD
- INCY 0.02
- ZBRA -1.26
- Stochastic Oscillator
- INCY 76.09
- ZBRA 41.67
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.